最新公布! 百济神州(06160)泽布替尼在头对头研究中取得持续获益的随访数据

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2390180336?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20231211/20231211162229_21666.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2023-12-11 16:21","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2390180336","market":"us","top_or_hot":-1,"title":"最新公布! 百济神州(06160)泽布替尼在头对头研究中取得持续获益的随访数据","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，2023年12月9日，百济神州(06160)在2023美国血液学会(ASH)年会上公布其自主研发抗癌药物泽布替尼(百悦泽®)治疗复发或难治性慢性淋巴细胞白血病(CLL)/小淋巴细胞淋巴瘤(SLL)患者的长期随访数据。数据显示，在全球3期头对头ALPINE试验中，与伊布替尼对比，泽布替尼持续取得无进展生存期(PFS)获益。根据百济神州展示的数据，在中位随访时间为39个月时，泽布...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1036211.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>最新公布! 百济神州(06160)泽布替尼在头对头研究中取得持续获益的随访数据</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n最新公布! 百济神州(06160)泽布替尼在头对头研究中取得持续获益的随访数据\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-11 16:21 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1036211.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，2023年12月9日，百济神州(06160)在2023美国血液学会(ASH)年会上公布其自主研发抗癌药物泽布替尼(百悦泽®)治疗复发或难治性慢性淋巴细胞白血病(CLL)/小淋巴细胞淋巴瘤(SLL)患者的长期随访数据。数据显示，在全球3期头对头ALPINE试验中，与伊布替尼对比，泽布替尼持续取得无进展生存期(PFS)获益。根据百济神州展示的数据，在中位随访时间为39个月时，泽布...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1036211.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0588546209.SGD","symbol_name":"Eastspring Investments - China Equity Fund AS SGD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1036211.html","article_id":"2390180336","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20231211/20231211162229_21666.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2390180336","pubTimestamp":1702282870,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"百济神州公布自主研发抗癌药物泽布替尼(百悦泽®)治疗复发或难治性慢性淋巴细胞白血病(CLL)/小淋巴细胞淋巴瘤(SLL)患者的长期随访数据。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4504":"桥水持仓","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1500":"做空集合股","BK1583":"高瓴概念","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓","06160":"百济神州","BK1161":"生物科技","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK4588":"碎股","BK4526":"热门中概股","BK1588":"回港中概股","BK4505":"高瓴资本持仓","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC"},"translate_title":"Latest announcement! Baekje Shenzhou (06160) Follow-up data of continuous benefit of zebutinib in head-to-head study","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BGNE":1,"06160":1},"content_text":"智通财经APP获悉，2023年12月9日，百济神州(06160)在2023美国血液学会(ASH)年会上公布其自主研发抗癌药物泽布替尼(百悦泽®)治疗复发或难治性慢性淋巴细胞白血病(CLL)/小淋巴细胞淋巴瘤(SLL)患者的长期随访数据。数据显示，在全球3期头对头ALPINE试验中，与伊布替尼对比，泽布替尼持续取得无进展生存期(PFS)获益。根据百济神州展示的数据，在中位随访时间为39个月时，泽布替尼和伊布替尼的PFS分别为64.9%和54.8%(HR: 0.68;  P=0.0011)。此前已公布的数据显示，在这项全球3期头对头研究中，当中位随访时间为29.6个月时，泽布替尼的无进展生存率为78.4%，而伊布替尼的无进展生存率为65.9%(HR:  0.65; P=0.0024)。凭借ALPINE研究在内的两项全球3期临床试验的积极数据，美国FDA已完全批准泽布替尼用于治疗CLL/SLL成人患者。在此次最新公布的数据中，泽布替尼的总生存期(OS)结果继续显示出有利的趋势，服用泽布替尼的患者中OS达到82.5%，而服用伊布替尼的患者则为79.6%存活。风险比为0.75，即服用泽布替尼的患者死亡风险降低25%。虽然这一差异未能达到在统计学的显著性，但ALPINE试验研究者Jennifer  Brown博士表示，CLL患者的生存期较长，许多患者通常可以存活至少20年，对患者进行这么长时间的随访是不可行的。她说，慢性淋巴细胞白血病(CLL)不同于急性淋巴细胞白血病(ALL)等更具侵袭性的血液恶性肿瘤，因为CLL患者长期生存，如果出现复发，还能服用其他治疗药物。而ALL患者在复发后对其他药物的反应不佳。Jennifer  Brown说：“真的希望能有一种有效的疗法能延长ALL患者的生命，因为当治疗失败时，他们就会死亡。但在CLL这类疾病中，我们还有其他选择。”亚特兰大希望之城(City of Hope Atlanta)的血液恶性肿瘤医学主任Sabarish Ayyappan医学博士同意Jennifer  Brown的评估。对ALPINE试验进行更长时间的随访可能会使OS数据曲线最终达到统计学意义，但这需要一段时间。Sabarish  Ayyappan说：“此次数据只是三年的随访期，我相信到五年或十年的随访，可能会看到OS曲线进一步分开。但在这个时间点上，我认为完全缓解率和PFS是我们所关注的。”","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2390180336","isCrawlerRequest":true}